RIPE Knowledge Graph
RIPE-KG · Version 1.1.0 · Resource

ripekg:work/10.1007%2Fs13318-014-0242-5

https://w3id.org/ripe/ripe-kg/work/10.1007%2Fs13318-014-0242-5
SubjectPredicateObject
ripekg:publication-details/RIPEAA805A88D874EA69CThe optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties ripe:concerns ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
ripekg:publication-details/RIPEAD0800A4DFB9CD804The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties ripe:concerns ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
ripekg:registry-evidence/RIPEAA805A88D874EA69C ripe:concerns ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
ripekg:registry-evidence/RIPEAD0800A4DFB9CD804 ripe:concerns ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
ripekg:research-integrity-assessment/RIPEAA805A88D874EA69C ripe:assesses ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
ripekg:research-integrity-assessment/RIPEAD0800A4DFB9CD804 ripe:assesses ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
ripekg:study-design-evidence/RIPEAA805A88D874EA69C ripe:concerns ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
ripekg:study-design-evidence/RIPEAD0800A4DFB9CD804 ripe:concerns ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties prism:doi 10.1007/s13318-014-0242-5
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties dcterms:creator ripekg:author/RIPEAU24E3FDEA2D68B77EMasato Tobinai
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties dcterms:creator ripekg:author/RIPEAU2BF1A8844241660FKiyohiko Nakai
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties dcterms:creator ripekg:author/RIPEAU43DFC22518D9BCB7Takehiko Kawanishi
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties dcterms:creator ripekg:author/RIPEAU4BDA912C737E7EA8Junko Hashimoto
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties dcterms:creator ripekg:author/RIPEAUD1D93350CB44FD5CSatofumi Iida
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties dcterms:title The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties http://purl.org/spar/cito/cites ripekg:work/RIPEW3BD78FD6BA6FBC20A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties http://purl.org/spar/cito/cites ripekg:work/RIPEW572353876E2F644BPopulation pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties http://purl.org/spar/cito/cites ripekg:work/RIPEW596368D59C3FE896Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties http://purl.org/spar/cito/cites ripekg:work/RIPEW7F5ED891C74EA6E4Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogencontaining bisphosphonates
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties http://purl.org/spar/cito/cites ripekg:work/RIPEW7FC984DB8694FA40Modelling the effects of ibandronate treatment on the time course of bone mineral density in osteoporotic postmenopausal women
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties http://purl.org/spar/cito/cites ripekg:work/RIPEW9FA661F0312CC967Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties http://purl.org/spar/cito/cites ripekg:work/RIPEWA05E6AAC8DFC131DMonthly oral ibandronate is well tolerated and efficacious in Japanese osteoporotic subjects
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties http://purl.org/spar/cito/cites ripekg:work/RIPEWA3B9C5B3DDB503DBClinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties http://purl.org/spar/cito/cites ripekg:work/RIPEWC5336ABDD0D16917Ibandronate: a clinical pharmacological and pharmacokinetic update
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties http://purl.org/spar/cito/cites ripekg:work/RIPEWF7D9A467E6288491Analytical methods for the quantification of ibandronate in body fluids and bone
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties rdf:type node1
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties rdf:type http://purl.org/spar/fabio/Work
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties rdf:type rdfs:Resource
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties rdf:type owl:Thing
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties rdf:type prov:Entity
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties rdf:type ripe:WorkWork
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties owl:sameAs https://semopenalex.org/work/W2036934145